Protagenic Therapeutics, Inc.\new Logo

Protagenic Therapeutics, Inc.\new

Developing novel peptide drugs to treat stress-related neuropsychiatric & CNS disorders.

PTIX | US

Overview

Corporate Details

ISIN(s):
US74365N2027 (+1 more)
LEI:
Country:
United States of America
Address:
149 FIFTH AVENUE, 10010 NEW YORK
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Protagenic Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a platform of first-in-class treatments for stress-related neuropsychiatric and central nervous system (CNS) disorders. The company's core technology leverages Teneurin C-terminal Associated Peptides (TCAPs), a novel class of neuropeptides designed to regulate the brain's stress response at a cellular level. Its lead drug candidate, PT00114, is in clinical development for various indications, including mood disorders, depression, and substance abuse. Protagenic aims to address unmet clinical needs by directly modulating the brain's maladaptive responses to stress. The company has announced a business combination with Phytanix to form a new entity, Phytanix, Inc., combining their respective drug development pipelines.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Protagenic Therapeutics, Inc.\new filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Protagenic Therapeutics, Inc.\new

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Protagenic Therapeutics, Inc.\new via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Medios AG Logo
Compounding patient-specific therapies and supplying specialty pharma for complex conditions.
Germany
ILM1
Develops cord blood stem cell therapies for osteoarthritis & infant lung disease, plus banking.
South Korea
078160
MediWound Ltd. Logo
Develops enzymatic therapies for non-surgical tissue repair in burns and chronic wounds.
United States of America
MDWD
Medizen Humancare Inc Co., Ltd Logo
Offers DTC genetic testing and genomic analysis for personalized disease risk prediction.
South Korea
236340
Medy-Tox Inc. Logo
Develops and markets botulinum toxins and dermal fillers for global aesthetic & therapeutic use.
South Korea
086900
MeiraGTx Holdings plc Logo
Develops genetic medicines for eye, salivary gland, and CNS disorders using gene regulation tech.
United States of America
MGTX
Meito  Sangyo  Co., Ltd. Logo
Produces food products and specialty chemicals for industrial and pharmaceutical applications.
Japan
2207
Merck & Co., Inc. Logo
A global biopharma developing innovative medicines, vaccines, and animal health products.
United States of America
MRK
Mereo BioPharma Group plc Logo
A clinical-stage biopharma developing and commercializing novel therapies for rare diseases.
United States of America
MREO
Mersana Therapeutics, Inc. Logo
Developing innovative antibody-drug conjugates using proprietary platforms to treat cancer.
United States of America
MRSN

Talk to a Data Expert

Have a question? We'll get back to you promptly.